Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.48 |
| ▸ | KCNJ1 | P48048 | 4/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | DRD3 | P35462 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2967590 | 0.92 | KCNH2 (0.44) | KCNH2KCNJ1CD274DRD2DRD3 | |
| SCHEMBL1619458 | 0.91 | FAAH (0.46) | KCNH2CD274DRD2DRD3PKM | |
| SCHEMBL4669235 | 0.89 | KCNH2 (0.44) | KCNH2KCNJ1CD274DRD2DRD3 | |
| SCHEMBL5318987 | 0.89 | CD274 (0.56) | KCNH2KCNJ1CD274DRD2DRD3 | |
| SCHEMBL5316212 | 0.89 | KCNH2 (0.46) | KCNH2KCNJ1CD274DRD2DRD3 | |
| SCHEMBL5316942 | 0.87 | LTA4H (0.46) | KCNH2KCNJ1L3MBTL1FAAH | |
| SCHEMBL5318392 | 0.86 | CD274 (0.58) | KCNH2CD274DRD2DRD3 | |
| SCHEMBL5317478 | 0.86 | CCR3 (0.54) | CD274DRD2DRD3 | |
| SCHEMBL4668152 | 0.86 | KCNH2 (0.44) | KCNH2CD274DRD2DRD3L3MBTL1 | |
| SCHEMBL5314521 | 0.86 | POLB (0.46) | KCNH2CD274DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1893619-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTMIAS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006135316-A1 | New oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | KCNH2 6/4885KCNJ1 65/4885CD274 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.